{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:34:41Z","timestamp":1773887681959,"version":"3.50.1"},"reference-count":45,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"unspecified","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"crossref","award":["ANR-15-CE36-0006-01"],"award-info":[{"award-number":["ANR-15-CE36-0006-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"name":"French National Agency for Medicines and Health Products Safety","award":["2020S012"],"award-info":[{"award-number":["2020S012"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,2,16]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the association between non-steroidal anti-inflammatory drugs (NSAIDs) and miscarriage, which remains elusive in the actual literature, using modelling approaches to mitigate time-related bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Nationwide, population-based retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>The study used data from the French National Mother-Child Register (EPI-MERES), developed from the French National Health Data System containing the health information (hospital admissions, drug dispensing, comorbidities, etc.) of about 99% French population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>4\u2009857\u2009907 pregnancies ended in a live birth, a stillbirth or a miscarriage from 2013 to 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Exposure to NSAIDs from 2\u2009weeks before conception to the 20th week of pregnancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main outcome measures<\/jats:title>\n                    <jats:p>Miscarriage (ie, spontaneous abortion before the 20th week of pregnancy) from the sixth week of pregnancy. The Cox regression with a time-dependent exposure that incorporated a 3-day lag was used to estimate HRs and their 95% CIs adjusted for maternal characteristics. The 3-day lag period allows for addressing protopathic bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, there were 163\u2009666 (3,37%) miscarriage cases, and 349\u2009294 (7.19%) pregnancies were exposed to NSAIDs. Unexposed pregnancies were used as the reference category in all analyses. In the main analysis, exposure to NSAIDs increased the risk of miscarriage (HR, 1.83; 95%\u2009CI 1.81 to 1.86). The effect of individual drugs was heterogeneous, with 7 of the 19 drugs evaluated shown to increase the risk (flurbiprofen had the highest risk (HR, 3.28; 95%\u2009CI 3.15 to 3.41)\u2009and naproxen the lowest (HR, 1.09; 95%\u2009CI 1.01 to 1.18)). In the sensitivity analyses, increasing the lag time decreased the estimated HR (from HR, 2.25; 95%\u2009CI 2.21 to 2.28 with no lag to HR, 1.56; 95%\u2009CI 1.54 to 1.59 with a 7-day lag). Overall, the risk of miscarriage remained statistically significant in all the analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study found that early exposure to NSAIDs could increase the risk of miscarriage. This finding contributes to the body of evidence on their safety profile and may help inform future recommendations for their use in pregnant women.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-111456","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:56:04Z","timestamp":1773870964000},"page":"e111456","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Association between exposure to non-steroidal anti-inflammatory drugs in pregnancy and miscarriage risk: a French nationwide retrospective cohort study"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0021-8371","authenticated-orcid":false,"given":"Chi-Hong","family":"Duong","sequence":"first","affiliation":[{"name":"High-dimensional Biostatistics for Drug Safety and Genomics, CESP, Villejuif, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Quentin","sequence":"additional","affiliation":[{"name":"High-dimensional Biostatistics for Drug Safety and Genomics, CESP, Villejuif, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Demailly","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Midwifery, ETHICS - EA 7446, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Quantin","sequence":"additional","affiliation":[{"name":"High-dimensional Biostatistics for Drug Safety and Genomics, CESP, Villejuif, \u00cele-de-France, France"},{"name":"Biostatistics and Bioinformatics (DIM), CHU Dijon Bourgogne, Dijon, Bourgogne-Franche-Comt\u00e9, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Escolano","sequence":"additional","affiliation":[{"name":"High-dimensional Biostatistics for Drug Safety and Genomics, CESP, Villejuif, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4814-6370","authenticated-orcid":false,"given":"J\u00e9r\u00e9mie","family":"Botton","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Paris-Saclay University, Orsay, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Tubert\u2010Bitter","sequence":"additional","affiliation":[{"name":"High-dimensional Biostatistics for Drug Safety and Genomics, CESP, Villejuif, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isma\u00efl","family":"Ahmed","sequence":"additional","affiliation":[{"name":"High-dimensional Biostatistics for Drug Safety and Genomics, CESP, Villejuif, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"2026031814553048000_16.3.e111456.1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004365","article-title":"Medication use in pregnancy: a cross-sectional, multinational web-based study","volume":"4","author":"Lupattelli","year":"2014","journal-title":"BMJ Open"},{"key":"2026031814553048000_16.3.e111456.2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40264-021-01117-4","article-title":"Dispensing of Potentially Harmful Prescription Drugs in 1.8 Million Pregnant Women in France: A Nationwide Study Based on Two Risk Classification Systems","volume":"44","author":"Bloti\u00e8re","year":"2021","journal-title":"Drug Saf"},{"key":"2026031814553048000_16.3.e111456.3","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deq323"},{"key":"2026031814553048000_16.3.e111456.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-006-0118-2"},{"key":"2026031814553048000_16.3.e111456.5","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.12192"},{"key":"2026031814553048000_16.3.e111456.6","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G428"},{"key":"2026031814553048000_16.3.e111456.7","doi-asserted-by":"crossref","first-page":"2253956","DOI":"10.1080\/14767058.2023.2253956","article-title":"Use of non-steroidal anti-inflammatory drugs in pregnancy and oligohydramnios: a review","volume":"36","author":"D\u2019Ambrosio","year":"2023","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2026031814553048000_16.3.e111456.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311253292202"},{"key":"2026031814553048000_16.3.e111456.9","unstructured":"FDA . Nonsteroidal anti-inflammatory drugs (nsaids): drug safety communication - avoid use of nsaids in pregnancy at 20 weeks or later. FDA; 2024. Available: https:\/\/www.fda.gov\/safety\/medical-product-safety-information\/nonsteroidal-anti-inflammatory-drugs-nsaids-drug-safety-communication-avoid-use-nsaids-pregnancy-20 [Accessed 11 Oct 2024]."},{"key":"2026031814553048000_16.3.e111456.10","unstructured":"Medicines and Healthcare products Regulatory Agency . Non-steroidal anti-inflammatory drugs (nsaids): potential risks following prolonged use after 20 weeks of pregnancy. GOVUK; 2024. Available: https:\/\/www.gov.uk\/drug-safety-update\/non-steroidal-anti-inflammatory-drugs-nsaids-potential-risks-following-prolonged-use-after-20-weeks-of-pregnancy [Accessed 3 Jul 2024]."},{"key":"2026031814553048000_16.3.e111456.11","unstructured":"ANSM . Dossier th\u00e9matique - traitement de la douleur durant la grosses. ANSM; 2024. Available: https:\/\/ansm.sante.fr\/dossiers-thematiques\/medicaments-et-grossesse\/traitement-de-la-douleur-durant-la-grossesse [Accessed 10 Oct 2024]."},{"key":"2026031814553048000_16.3.e111456.12","unstructured":"New Zealand Medicines and Medical Devices Safety Authority . Non-steroidal anti-inflammatory drugs (nsaids): avoid use in pregnancy. 2024. Available: https:\/\/medsafe.govt.nz\/profs\/PUArticles\/September2022\/Non-steroidal-anti-inflammatory%20drugs-NSAIDs-avoid-use%20in-pregnancy.html [Accessed 3 Jul 2024]."},{"key":"2026031814553048000_16.3.e111456.13","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/1471-0528.16670","article-title":"Early exposure of pregnant women to non\u2010steroidal anti\u2010inflammatory drugs delivered outside hospitals and preterm birth risk: nationwide cohort study","volume":"128","author":"Quantin","year":"2021","journal-title":"BJOG"},{"key":"2026031814553048000_16.3.e111456.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004183","article-title":"Neonatal and maternal adverse outcomes and exposure to nonsteroidal anti-inflammatory drugs during early pregnancy in South Korea: A nationwide cohort study","volume":"20","author":"Choi","year":"2023","journal-title":"PLoS Med"},{"key":"2026031814553048000_16.3.e111456.15","doi-asserted-by":"publisher","DOI":"10.1016\/J.REPROTOX.2024.108561"},{"key":"2026031814553048000_16.3.e111456.16","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3182595671"},{"key":"2026031814553048000_16.3.e111456.17","doi-asserted-by":"crossref","first-page":"C532","DOI":"10.1152\/ajpcell.00430.2022","article-title":"Nonsteroidal anti-inflammatory drugs and implications for the cyclooxygenase pathway in embryonic development","volume":"324","author":"Leathers","year":"2023","journal-title":"Am J Physiol Cell Physiol"},{"key":"2026031814553048000_16.3.e111456.18","doi-asserted-by":"publisher","DOI":"10.2174\/138920012800166607"},{"key":"2026031814553048000_16.3.e111456.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7411.368"},{"key":"2026031814553048000_16.3.e111456.20","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.110454"},{"key":"2026031814553048000_16.3.e111456.21","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bcp.12653","article-title":"NSAIDs and spontaneous abortions - true effect or an indication bias?","volume":"80","author":"Daniel","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2026031814553048000_16.3.e111456.22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.reprotox.2018.05.003","article-title":"No evidence of adverse pregnancy outcome after exposure to ibuprofen in the first trimester - Evaluation of the national Embryotox cohort","volume":"79","author":"Dathe","year":"2018","journal-title":"Reprod Toxicol"},{"key":"2026031814553048000_16.3.e111456.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2018.06.002"},{"key":"2026031814553048000_16.3.e111456.24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00228-021-03222-w","article-title":"Maternal non-steroidal anti-inflammatory drug exposure during pregnancy and risk of miscarriage: a systematic review and meta-analysis","volume":"78","author":"Ying","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"2026031814553048000_16.3.e111456.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.322.7281.266"},{"key":"2026031814553048000_16.3.e111456.26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7431.109"},{"key":"2026031814553048000_16.3.e111456.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2012.02172.x"},{"key":"2026031814553048000_16.3.e111456.28","unstructured":"FDA . FDA drug safety communication: fda has reviewed possible risks of pain medicine use during pregnancy. FDA; 2019. Available: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-has-reviewed-possible-risks-pain-medicine-use-during-pregnancy [Accessed 15 Nov 2024]."},{"key":"2026031814553048000_16.3.e111456.29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ajog.2014.09.028","article-title":"Immortal time bias in drug safety cohort studies: spontaneous abortion following nonsteroidal antiinflammatory drug exposure","volume":"212","author":"Daniel","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"2026031814553048000_16.3.e111456.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2016.07.017"},{"key":"2026031814553048000_16.3.e111456.31","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/ppe.12967","article-title":"Risk of spontaneous abortion after periconceptional medication use: Time to tackle the methodological challenges","volume":"37","author":"van Gelder","year":"2023","journal-title":"Paediatr Perinat Epidemiol"},{"key":"2026031814553048000_16.3.e111456.32","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1360"},{"key":"2026031814553048000_16.3.e111456.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.respe.2017.05.004"},{"key":"2026031814553048000_16.3.e111456.34","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.therap.2024.05.003","article-title":"Use of the French National Health Data System (SNDS) in pharmacoepidemiology: A systematic review in its maturation phase","volume":"79","author":"Maillard","year":"2024","journal-title":"Therapies"},{"key":"2026031814553048000_16.3.e111456.35","doi-asserted-by":"crossref","first-page":"101539","DOI":"10.1016\/j.respe.2023.101539","article-title":"Registre national de donn\u00e9es M\u00e8res-Enfants \u00e0 partir du Syst\u00e8me national des donn\u00e9es de sant\u00e9 pour des \u00e9tudes pharmaco-\u00e9pid\u00e9miologiques","volume":"71","author":"Miranda","year":"2023","journal-title":"Revue d\u2019\u00c9pid\u00e9miologie et de Sant\u00e9 Publique"},{"key":"2026031814553048000_16.3.e111456.36","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000001745"},{"key":"2026031814553048000_16.3.e111456.37","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-9-33","article-title":"Ecological association between a deprivation index and mortality in France over the period 1997 - 2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death","volume":"9","author":"Rey","year":"2009","journal-title":"BMC Public Health"},{"key":"2026031814553048000_16.3.e111456.38","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwm324"},{"key":"2026031814553048000_16.3.e111456.39","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/81.3.515"},{"key":"2026031814553048000_16.3.e111456.40","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181a663cc"},{"key":"2026031814553048000_16.3.e111456.41","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/EDE.0000000000001107","article-title":"Use of Time-Dependent Propensity Scores to Adjust Hazard Ratio Estimates in Cohort Studies with Differential Depletion of Susceptibles","volume":"31","author":"Wyss","year":"2020","journal-title":"Epidemiology (Sunnyvale)"},{"key":"2026031814553048000_16.3.e111456.42","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5984"},{"key":"2026031814553048000_16.3.e111456.43","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/pds.2238","article-title":"Letter to the editor","volume":"20","author":"Schneeweiss","year":"2011","journal-title":"Pharmacoepidemiology and Drug"},{"key":"2026031814553048000_16.3.e111456.44","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2152"},{"key":"2026031814553048000_16.3.e111456.45","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5346"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-111456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:56:08Z","timestamp":1773870968000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-111456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,18]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bmjopen-2025-111456"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-111456","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}